RICARDO ROMITI
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina
LIM/53 - Laboratório de Micologia, Hospital das Clínicas, Faculdade de Medicina
LIM/50 - Laboratório de Patologia das Moléstias Infecciosas, Hospital das Clínicas, Faculdade de Medicina
LIM/53 - Laboratório de Micologia, Hospital das Clínicas, Faculdade de Medicina
LIM/50 - Laboratório de Patologia das Moléstias Infecciosas, Hospital das Clínicas, Faculdade de Medicina
6 resultados
Resultados de Busca
Agora exibindo 1 - 6 de 6
- Therapeutic response and survival time of immunobiologicals in patients with moderate to severe psoriasis(2022) MOTA, Cynthia Cristina Ferreira; ROMITI, Ricardo; ARNONE, Marcelo; HIRAYAMA, Andre Luis da Silva; TAKAHASHI, Maria Denise Fonseca
- Diagnostic and therapeutic guidelines for plaque psoriasis - Brazilian Society of Dermatology(2019) ARNONE, Marcelo; TAKAHASHI, Maria Denise Fonseca; CARVALHO, Andre Vicente Esteves de; BERNARDO, Wanderley Marques; BRESSAN, Aline Lopes; RAMOS, Andrea Machado Coelho; TERENA, Aripuana Coberio; SOUZA, Cacilda da Silva; NUNES, Daniel Holthausen; BORTOLETTO, Maria Cecilia de Carvalho; OLIVEIRA, Maria de Fatima Santos Paim de; NEFFA, Jane Marcy; FIERI, Luciana Cristina; AZULAY-ABULAFIA, Luna; FELIX, Paulo Antonio Oldani; MAGALHAES, Renata Ferreira; ROMITIL, Ricardo; JAIME, Tatiana JerezPsoriasis is a chronic inflammatory disease that affects 1.3% of the Brazilian population. The most common clinical manifestations are erythematous, scaling lesions that affect both genders and can occur on any anatomical site, preferentially involving the knees, elbows, scalp and genitals. Besides the impact on the quality of life, the systemic nature of the disease makes psoriasis an independent risk factor for cardiovascular disease, especially in young patients with severe disease. By an initiative of the Brazilian Society of Dermatology, dermatologists with renowned clinical experience in the management of psoriasis were invited to form a work group that, in a partnership with the Brazilian Medical Association, dedicated themselves to create the Plaque Psoriasis Diagnostic and Treatment Guidelines. The relevant issues for the diagnosis (evaluation of severity and comorbidities) and treatment of plaque psoriasis were defined. The issues generated a search strategy in the Medline-PubMed database up to July 2018. Subsequently, the answers to the questions of the recommendations were devised, and each reference selected presented the respective level of recommendation and strength of scientific evidence. The final recommendations for making up the final text were worded by the coordinators.
- Infliximab partially impairs the anti-Mycobacterium tuberculosis immune responses of severe psoriasis patients with positive tuberculin skin-test(2012) SILVA, L. C. R.; GELUK, A.; ARNONE, M.; ROMITI, R.; FRANKEN, K. C. L. M.; DUARTE, A. J. S.; TAKAHASHI, M. D. F.; BENARD, G.Background Infliximab and etarnecept are now widely used for treating severe psoriasis. However, these drugs, especially infliximab, increased the risk of tuberculosis reactivation. Surprisingly, epidemiological data suggest that the tuberculosis rate in patients taking infliximab in Sao Paulo State, Brazil, is similar to that of some developed, non-endemic countries. Objective The aim of this study was to better understand the effect of infliximab on Mycobacterium tuberculosis (Mtb) immune responses of psoriasis patients in an endemic setting (Brazil). Methods We evaluated the tuberculosis-specific immune responses of severe psoriasis patients and healthy individuals, both tuberculin skin test (TST) positive, in the presence/absence of infliximab. Patients had untreated severe psoriasis, no co-morbidities affecting the immune responses and a TST >10 mm. Healthy TST+ (>10 mm) individuals were evaluated in parallel. PBMC cultures from both groups were stimulated with different Mycobacterium tuberculosis (Mtb) antigens (ESAT-6, 85B and Mtb lysate) and phytohemagglutinin, with or without infliximab (5 mu g/mL). Parameters evaluated were TNF-alpha, IFN-gamma and IL-10 secretion by ELISA, overnight IFN-gamma ELISpot and lymphocyte proliferative response (LPR). Results Infliximab almost abolished TNF-alpha detection in PBMC supernatants of both groups. It also significantly reduced the LPR to phytohemagglutinin and the Mtb antigens as well as the IFN-gamma levels secreted into day 5 supernatants in both groups. There was no concomitant exaggerated IL-10 secretion that could account for the decreases in these responses. ELISpot showed that, contrasting with the central-memory responses above, infliximab did not affect effector-memory INF-gamma-releasing T-cell numbers. Conclusions Infliximab affected some, but not all aspects of the in vitro antituberculosis immune responses tested. The preserved effector-memory responses, putatively related to exposure to environmental mycobacteria, may help to explain the lower than expected susceptibility to tuberculosis reactivation in our setting. Received: 29 December 2010; Accepted: 9 March 2011
conferenceObject INCREASED TOLL LIKE RECEPTOR 2 (TLR2) EXPRESSION ON PERIPHERAL BLOOD MONOCYTES FROM PATIENTS WITH ANTI-TNF INDUCED PSORIASIS SUGGESTS A ROLE FOR A GRAM-POSITIVE INFLAMMATORY TRIGGER(2016) VALKINIR, D. E. J.; FERNANDEZ, V. V.; NOGUEIRA, M. A. D. S.; ROMITI, R.; AMONE, M.; HIRAYAMA, A. L. D. S.; TAKAHASHI, M. D. F.; CARRASCO, S.; SAMPAIO-BARROS, P.; MORAES, J.; GONCALVES, C.; SAAD, C.; GOLDENSTEIN-SCHAINBERG, C.- The many faces of tuberculosis of the oral mucosa - three cases with distinct pathomechanisms(2018) NICO, M. M. S.; GAVIOLI, C. F. B.; DABRONZO, M. L. D.; ROMITI, R.; TAKAHASHI, M. D.; LOURENCO, S. V.
bookPart Erupções Eritematoescamosas(2016) ROMITI, Ricardo; TAKAHASHI, Maria Denise Fonseca